Brimonidine tartrate eye drops

Brimonidine tartrate.

This product is suitable for reducing intraocular pressure in patients with open-angle glaucoma and ocular hypertension.

The usual dose is to instill 1 drop into the patient's eye 2 times a day. If the condition cannot be well controlled, 1 drop can be added in the afternoon.

Approximately 1030% of the subjects experienced the following adverse reactions, in descending order, including dry mouth, eye congestion, burning and stinging sensation, headache, blurred vision, fatigue/tiredness, conjunctival follicles, ocular allergic reaction and ocular itching. Approximately 39% of the subjects experienced the following adverse reactions, in descending order, including corneal staining/erosion, photophobia, eyelid erythema, eye soreness/pain, dry eyes, tearing, upper respiratory tract symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, eye irritation, gastrointestinal symptoms, weakness, conjunctival blanching, abnormal vision and muscle pain. Less than 3% of the patients experienced the following adverse reactions, including eyelid crusting, conjunctival hemorrhage, abnormal taste, insomnia, increased conjunctival secretions, depression, hypertension, anxiety, palpitations, dry nose and syncope.

This product is contraindicated in patients who are allergic to bronidine tartrate or any of its ingredients, and is also contraindicated in patients receiving treatment with monoamine chlorination inhibitors.

Although no special studies have been conducted on drug interactions of this product, the possibility of additive or enhanced effects with central nervous system depressants (alcohol, barbiturates, opium preparations, sedatives or anesthetics) should be considered. Clinical studies have not found that this product has a significant effect on pulse or blood pressure, but since alpha receptor agonists can also slow the pulse or make blood pressure drugs and/or cardiotonic drugs, attention should also be paid. The literature reports that tricyclic antidepressants weaken the antihypertensive effect of systemic clonidine. Whether the simultaneous use of such drugs will interfere with the hypotensive effect of this product is not clear. There is no data on whether the use of this product affects the high level of catecholamines in the circulation. However, this product should be used with caution when patients take tricyclic antidepressants that can affect the metabolism or uptake of amines in the circulation.

0.0015